Clarivate Engages in Sale Discussions for Life Sciences & Healthcare Business
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy CLVT?
Source: seekingalpha
- Sale Plan: Clarivate is actively discussing the sale of its Life Sciences & Healthcare business with interested parties, aiming to refocus on academia, government, and intellectual property markets through this strategic move.
- Financial Advisor Appointment: The company has retained Morgan Stanley as its financial advisor to assist in the potential sale, with anticipated proceeds aimed at reducing leverage and strengthening the balance sheet.
- Stock Price Reaction: Following the announcement, Clarivate's shares rose approximately 6% in early trading, reflecting market optimism regarding the company's strategic shift and future growth potential.
- Transaction Uncertainty: While the company expresses a positive outlook on the sale process, it also notes that “there can be no assurances that the sale process will result in a transaction,” highlighting the risks and uncertainties associated with potential deals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLVT
Wall Street analysts forecast CLVT stock price to rise
5 Analyst Rating
0 Buy
3 Hold
2 Sell
Moderate Sell
Current: 2.310
Low
3.00
Averages
3.90
High
5.00
Current: 2.310
Low
3.00
Averages
3.90
High
5.00
About CLVT
Clarivate Plc is a global provider of transformative intelligence. The Company offers enriched data, insights and analytics, workflow solutions and expert services in the areas of Academia & Government (A&G), Intellectual Property (IP) and Life Sciences & Healthcare (LS&H). Within the A&G segment, the Company offers solutions across various areas, which include scientific and academic research, information solutions and library software. Its ProQuest One solutions provide access to multidisciplinary curated content across a variety of formats, including data bases, dissertations, news, primary sources, books, and video. Within the IP segment, the Company provides IP data, software, and expertise to other companies to manage and protect critical IP assets. This segment's service offerings include IP management software, Patent services and Brand IP solutions, among others. Within the LS&H segment, the Company offers solutions across research and development, commercial and Medtech.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Plummets Amid Escalating Geopolitical Tensions
- Oil Price Surge: The escalating conflict between the U.S., Israel, and Iran has driven West Texas Intermediate crude oil prices up by 6.4% to $75.8 per barrel, marking the largest two-day rally since March 2022, indicating heightened market concerns over energy supply disruptions.
- Market Panic Intensifies: The CBOE Volatility Index surged by 6% to 22.74, reflecting increased investor fear regarding short-term market volatility, with all 11 S&P 500 sectors trading in the red, showcasing widespread market pressure.
- Fed Policy Expectations Shift: Amid rising inflation fears, the 10-year Treasury yield climbed from 3.97% last Friday to approximately 4.06%, leading traders to reprice expectations for Fed rate cuts, now anticipating fewer chances of cuts in 2026.
- Strong Dollar Impact: The U.S. dollar index is on track for its largest two-day gain since February 2023, resulting in significant declines in gold and silver prices, with spot gold falling 4.6% to around $5,080 per ounce and silver plummeting 7.8% to $82 per ounce, highlighting the dollar's pressure on commodity markets.
See More
HG Vora Capital Sells All Clarivate Shares in Q4
- Shareholding Change: HG Vora Capital Management sold all 11,125,000 shares of Clarivate in Q4 2026, resulting in no holdings at quarter-end and a net position change of $42.61 million, indicating a cautious outlook on Clarivate's future prospects.
- Market Performance: As of Tuesday, Clarivate shares were priced at $2.45, down 42% over the past year, significantly underperforming the S&P 500, which rose about 16% during the same period, reflecting its weak market position.
- Financial Overview: Clarivate generated $2.46 billion in revenue in 2025, down from $2.56 billion in 2024, although it produced $365.3 million in free cash flow, with recurring revenue now representing 88% of total sales, indicating an improvement in business quality.
- Strategic Restructuring: Clarivate is actively exploring the sale of its Life Sciences segment to reduce its $4.47 billion debt burden; if recurring revenue growth and deleveraging accelerate, the current depressed price could become attractive, but disappointing divestitures may continue to weigh on returns.
See More
HG Vora Completely Exits Clarivate Shares
- Position Change: HG Vora sold 11,125,000 shares of Clarivate in Q4, resulting in a $42.61 million decrease in position value, indicating a significant loss of confidence in the company.
- Financial Performance: Clarivate generated $2.46 billion in revenue for 2025, down from $2.56 billion in 2024, reflecting challenges in its market competitiveness and an ongoing strategic reset.
- Debt Pressure: Despite a 1.8% increase in annualized contract value, the company's total debt remains at $4.47 billion, suggesting HG Vora's exit may stem from concerns over the firm's future financial health.
- Market Outlook: With recurring revenue now representing 88% of total sales, if Clarivate can accelerate deleveraging and revenue growth, today's depressed stock price could become attractive; however, disappointing divestitures may continue to weigh on returns.
See More
Clarivate Reports Strong Q4 Results and Optimistic 2026 Guidance
- Financial Performance Exceeds Expectations: Clarivate reported Q4 2025 revenue of $617 million, surpassing analysts' estimates of $604.8 million, indicating strong performance in the research database and brand management sectors, which boosts market confidence.
- Improved Profitability: The company posted adjusted earnings per share (EPS) of $0.20, exceeding the anticipated $0.16, reflecting ongoing improvements in profitability that may attract more investor interest.
- Free Cash Flow Growth: Clarivate reported Q4 2025 free cash flow of $89.2 million, a 50.9% year-over-year increase, despite a 6.9% decline in sales, demonstrating enhanced operational efficiency.
- Optimistic 2026 Guidance: Management projects adjusted EPS for 2026 between $0.70 and $0.80, with the midpoint indicating an 8.7% year-over-year increase, while free cash flow is expected to range from $365 million to $435 million, highlighting the company's growth potential.
See More
Clarivate Shares Surge 31.4% Following Strong Q4 Earnings Report
- Earnings Beat: Clarivate reported non-GAAP earnings of $0.20 per share and sales of $617 million for Q4, surpassing analyst expectations of $0.16 and $604.8 million, indicating strong market performance despite a year-over-year revenue decline of approximately 7%.
- Stable Subscription Revenue: Subscription revenue decreased slightly from $407 million to $405.8 million, yet organic growth showed a 1% increase, reflecting the company's resilience in maintaining its customer base and revenue streams, which boosts market confidence.
- Optimistic Outlook: Clarivate is targeting a 10% growth in free cash flow this year, with annual contract value expected to grow between 2% and 3%, and recurring organic revenue projected to rise by 1% to 2%, providing investors with confidence that contributed to the stock surge.
- Strategic Restructuring: The company is in active discussions to sell its life sciences and healthcare business to reduce debt and improve its balance sheet, while planning to expand in academia and government and intellectual property sectors, which could lay a foundation for future growth.
See More
Clarivate Exceeds Q4 Sales and Earnings Expectations
- Earnings Beat: Clarivate reported non-GAAP earnings of $0.20 per share and sales of $617 million in Q4, surpassing analyst expectations of $0.16 and $604.8 million, indicating strong market performance.
- Optimistic Sales Outlook: Although revenue declined approximately 7% year-over-year, the drop was less severe than anticipated, with subscription revenue slightly down to $405.8 million but showing a 1% organic growth, reflecting stability in core operations.
- Cash Flow and Contract Value Targets: The company is targeting a 10% growth in free cash flow this year, forecasting a 2% to 3% increase in annual contract value, while organic revenue is projected to rise between 1% and 2%, which will enhance its financial health.
- Strategic Business Sale: Clarivate is in active discussions to sell its life sciences and healthcare business, intending to use the proceeds to reduce debt, improve its balance sheet, and expand in academia and government as well as intellectual property sectors, demonstrating a strategic focus on future growth.
See More
Wall Street Plummets Amid Escalating Geopolitical Tensions
- Oil Price Surge: The escalating conflict between the U.S., Israel, and Iran has driven West Texas Intermediate crude oil prices up by 6.4% to $75.8 per barrel, marking the largest two-day rally since March 2022, indicating heightened market concerns over energy supply disruptions.
- Market Panic Intensifies: The CBOE Volatility Index surged by 6% to 22.74, reflecting increased investor fear regarding short-term market volatility, with all 11 S&P 500 sectors trading in the red, showcasing widespread market pressure.
- Fed Policy Expectations Shift: Amid rising inflation fears, the 10-year Treasury yield climbed from 3.97% last Friday to approximately 4.06%, leading traders to reprice expectations for Fed rate cuts, now anticipating fewer chances of cuts in 2026.
- Strong Dollar Impact: The U.S. dollar index is on track for its largest two-day gain since February 2023, resulting in significant declines in gold and silver prices, with spot gold falling 4.6% to around $5,080 per ounce and silver plummeting 7.8% to $82 per ounce, highlighting the dollar's pressure on commodity markets.
See More
HG Vora Capital Sells All Clarivate Shares in Q4
- Shareholding Change: HG Vora Capital Management sold all 11,125,000 shares of Clarivate in Q4 2026, resulting in no holdings at quarter-end and a net position change of $42.61 million, indicating a cautious outlook on Clarivate's future prospects.
- Market Performance: As of Tuesday, Clarivate shares were priced at $2.45, down 42% over the past year, significantly underperforming the S&P 500, which rose about 16% during the same period, reflecting its weak market position.
- Financial Overview: Clarivate generated $2.46 billion in revenue in 2025, down from $2.56 billion in 2024, although it produced $365.3 million in free cash flow, with recurring revenue now representing 88% of total sales, indicating an improvement in business quality.
- Strategic Restructuring: Clarivate is actively exploring the sale of its Life Sciences segment to reduce its $4.47 billion debt burden; if recurring revenue growth and deleveraging accelerate, the current depressed price could become attractive, but disappointing divestitures may continue to weigh on returns.
See More
HG Vora Completely Exits Clarivate Shares
- Position Change: HG Vora sold 11,125,000 shares of Clarivate in Q4, resulting in a $42.61 million decrease in position value, indicating a significant loss of confidence in the company.
- Financial Performance: Clarivate generated $2.46 billion in revenue for 2025, down from $2.56 billion in 2024, reflecting challenges in its market competitiveness and an ongoing strategic reset.
- Debt Pressure: Despite a 1.8% increase in annualized contract value, the company's total debt remains at $4.47 billion, suggesting HG Vora's exit may stem from concerns over the firm's future financial health.
- Market Outlook: With recurring revenue now representing 88% of total sales, if Clarivate can accelerate deleveraging and revenue growth, today's depressed stock price could become attractive; however, disappointing divestitures may continue to weigh on returns.
See More
Clarivate Reports Strong Q4 Results and Optimistic 2026 Guidance
- Financial Performance Exceeds Expectations: Clarivate reported Q4 2025 revenue of $617 million, surpassing analysts' estimates of $604.8 million, indicating strong performance in the research database and brand management sectors, which boosts market confidence.
- Improved Profitability: The company posted adjusted earnings per share (EPS) of $0.20, exceeding the anticipated $0.16, reflecting ongoing improvements in profitability that may attract more investor interest.
- Free Cash Flow Growth: Clarivate reported Q4 2025 free cash flow of $89.2 million, a 50.9% year-over-year increase, despite a 6.9% decline in sales, demonstrating enhanced operational efficiency.
- Optimistic 2026 Guidance: Management projects adjusted EPS for 2026 between $0.70 and $0.80, with the midpoint indicating an 8.7% year-over-year increase, while free cash flow is expected to range from $365 million to $435 million, highlighting the company's growth potential.
See More
Clarivate Shares Surge 31.4% Following Strong Q4 Earnings Report
- Earnings Beat: Clarivate reported non-GAAP earnings of $0.20 per share and sales of $617 million for Q4, surpassing analyst expectations of $0.16 and $604.8 million, indicating strong market performance despite a year-over-year revenue decline of approximately 7%.
- Stable Subscription Revenue: Subscription revenue decreased slightly from $407 million to $405.8 million, yet organic growth showed a 1% increase, reflecting the company's resilience in maintaining its customer base and revenue streams, which boosts market confidence.
- Optimistic Outlook: Clarivate is targeting a 10% growth in free cash flow this year, with annual contract value expected to grow between 2% and 3%, and recurring organic revenue projected to rise by 1% to 2%, providing investors with confidence that contributed to the stock surge.
- Strategic Restructuring: The company is in active discussions to sell its life sciences and healthcare business to reduce debt and improve its balance sheet, while planning to expand in academia and government and intellectual property sectors, which could lay a foundation for future growth.
See More
Clarivate Exceeds Q4 Sales and Earnings Expectations
- Earnings Beat: Clarivate reported non-GAAP earnings of $0.20 per share and sales of $617 million in Q4, surpassing analyst expectations of $0.16 and $604.8 million, indicating strong market performance.
- Optimistic Sales Outlook: Although revenue declined approximately 7% year-over-year, the drop was less severe than anticipated, with subscription revenue slightly down to $405.8 million but showing a 1% organic growth, reflecting stability in core operations.
- Cash Flow and Contract Value Targets: The company is targeting a 10% growth in free cash flow this year, forecasting a 2% to 3% increase in annual contract value, while organic revenue is projected to rise between 1% and 2%, which will enhance its financial health.
- Strategic Business Sale: Clarivate is in active discussions to sell its life sciences and healthcare business, intending to use the proceeds to reduce debt, improve its balance sheet, and expand in academia and government as well as intellectual property sectors, demonstrating a strategic focus on future growth.
See More
